Our Pipeline

Our goal is to transform the prevention and treatment of infectious diseases and cancers to significantly improve the lives of patients by developing and commercializing a new class of  immunotherapeutics.

We are leveraging our modular arenavirus platform to develop the following product candidates for multiple infectious diseases and cancers - the efficacy of our replicating (TheraT®) and non-replicating (VaxWave®) platforms is being tested all across our pipeline:

Compound
Antigen
Target
Pre-ClinicalPre.
Phase1Ph1.
Phase2Ph2.
Phase3Ph3.
Anticipated Milestones
Global Rights
HB-101*
(VaxWave®)
gB/pp65
CMV
Preliminary data late 2020
HBV
Therapy
Undisclosed
HBV
Advancing closer to clinical studies
Gilead Investors Biotech
HIV
Therapy
Undisclosed
HIV
Advancing closer to clinical studies
Gilead Investors Biotech
HB-201**
(TheraT® LCMV)
E6/E7
HPV16+ Cancer
Interim data late 2020/early 2021
HB-202/201
(TheraT® PICV/
TheraT® LCMV)
E6/E7
HPV16+ Cancer
FPI Q4 2020
HB-301
(TheraT®)
PSA/PSMA/PAP
Prostate Cancer
Infectious
Oncology

*ClinicalTrials.gov Identifier: NCT03629080; **ClinicalTrials.gov Identifier: NCT04180215